A preliminary study on plasma concentration, short-term efficacy, and safety profile of dolutegravir in Chinese people with HIV

References

• Han M. Analysis of the epidemic situation of AIDS and prospects for prevention and control in China. Chin J AIDS STD. 2023;29(3):247–250. doi: 10.13419/j.cnki.aids.2023.03.01
   Google Scholar
• Sun C, Li J, Liu X, et al. HIV/AIDS late presentation and its associated factors in China from 2010 to 2020: a systematic review and meta-analysis. AIDS Res Ther. 2021;18(1):96.
   PubMed Web of Science ®Google Scholar
• WHO Guidelines Approved by the Guidelines Review Committee. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021.
   Google Scholar
• Li D, Fu Q, Du X, et al. Development and validation of an HPLC method for quantification of dolutegravir in human plasma. Biomed Chromatogr. 2023;37(10):e5708. doi: 10.1002/bmc.5708
   PubMed Web of Science ®Google Scholar
• Inker LA, Eneanya ND, Coresh J, et al. Chronic kidney disease epidemiology collaboration. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737–1749. doi: 10.1056/NEJMoa2102953
   PubMed Web of Science ®Google Scholar
• Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):254–258. doi: 10.1128/aac.00842-09
   PubMed Web of Science ®Google Scholar
• Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25(14):1737–1745. doi: 10.1097/QAD.0b013e32834a1dd9
   PubMed Web of Science ®Google Scholar
• van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48-week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111–118. doi: 10.1016/S1473-3099(11)70290-0
   PubMed Web of Science ®Google Scholar
• Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis. 2013;207(5):740–748. doi: 10.1093/infdis/jis750
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700–708. doi: 10.1016/S0140-6736(13)61221-0
   PubMed Web of Science ®Google Scholar
• Le X, Guo X, Sun J, et al. Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex. Int J Infect Dis. 2022;116:147–150. doi: 10.1016/j.ijid.2022.01.001
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48-week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735–743. doi: 10.1016/S0140-6736(12)61853-4
   PubMed Web of Science ®Google Scholar
• Bollen P, Freriksen J, Konopnicki D, et al. The effect of pregnancy on the pharmacokinetics of total and unbound dolutegravir and its main metabolite in women living with human immunodeficiency virus. Clin Infect Dis. 2021;72(1):121–127. doi: 10.1093/cid/ciaa006
   PubMed Web of Science ®Google Scholar
• Zhang J, Hayes S, Sadler BM, et al. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Br J Clin Pharmacol. 2015;80(3):502–514. doi: 10.1111/bcp.12639
   PubMed Web of Science ®Google Scholar
• Liu B, Du Y, Wu Y, et al. Trends in obesity and adiposity measures by race or ethnicity among adults in the United States 2011-18: population based study. BMJ. 2021;372:n365. doi: 10.1136/bmj.n365
   PubMedGoogle Scholar
• Marques A, Peralta M, Naia A, et al. Prevalence of adult overweight and obesity in 20 European countries, 2014. Eur J Public Health. 2018;28(2):295–300. doi: 10.1093/eurpub/ckx143
   PubMed Web of Science ®Google Scholar
• Chen S, St Jean P, Borland J, et al. Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics. Pharmacogenomics. 2014;15(1):9–16. doi: 10.2217/pgs.13.190
   PubMed Web of Science ®Google Scholar
• Yagura H, Watanabe D, Kushida H, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 2017;17(1):622. doi: 10.1186/s12879-017-2717-x
   PubMedGoogle Scholar
• Kaniwa N, Kurose K, Jinno H, et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American. Drug Metab Dispos. 2005;33(3):458–465. doi: 10.1124/dmd.104.001800
   PubMed Web of Science ®Google Scholar
• Zhang A, Xing Q, Qin S, et al. Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations. Pharmacogenomics J. 2007;7(5):333–338. doi: 10.1038/sj.tpj.6500424
   PubMed Web of Science ®Google Scholar
• Ando Y, Fujita K, Sasaki Y, et al. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Curr Opin Mol Ther. 2007;9(3):258–262.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55(2):813–821. doi: 10.1128/AAC.01209-10
   PubMed Web of Science ®Google Scholar
• Cottrell ML, Hadzic T, Kashuba ADM. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013;52(11):981–994. doi: 10.1007/s40262-013-0093-2
   PubMed Web of Science ®Google Scholar